HAVCR2 and lung adenocarcinoma: The latter mechanism has been described in a mouse model of lung adenocarcinoma, where adaptive resistance to anti-PD-1 treatment was associated with an upregulation of TIM-3 on PD-1+ T cells in the tumor (47).